4:07 PM ET
10-Q
Financial Results
X4 Pharmaceuticals Q3 2026 Results: Net Loss of $20.2M, Loss Narrows
X4 Pharmaceuticals reported total revenue of $14.4 million for the first nine months of 2026, a decrease from $32.5 million in the prior year period, primarily due to lower license revenue. Net product revenue from XOLREMDI grew to $7.6 million year-to-date, while the company reduced its nine-month operating loss to $56.7 million through significant cuts in research, development, and administrative expenses.
- Key figure
- Net loss $20.2M